Genmab A/S (NASDAQ:GMAB) Given Consensus Rating of “Moderate Buy” by Analysts

Genmab A/S (NASDAQ:GMAB) has received an average rating of “Moderate Buy” from the ten research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $45.20.

A number of equities research analysts have issued reports on GMAB shares. BMO Capital Markets reiterated an “outperform” rating and issued a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Wednesday, January 8th. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Finally, Redburn Atlantic began coverage on Genmab A/S in a research note on Tuesday, October 8th. They set a “buy” rating for the company.

Institutional Trading of Genmab A/S

A number of institutional investors and hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp increased its stake in shares of Genmab A/S by 4.9% in the second quarter. Bank of New York Mellon Corp now owns 70,171 shares of the company’s stock worth $1,763,000 after purchasing an additional 3,283 shares during the period. Rhumbline Advisers increased its position in Genmab A/S by 7.1% in the 2nd quarter. Rhumbline Advisers now owns 18,694 shares of the company’s stock worth $470,000 after buying an additional 1,236 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of Genmab A/S by 360.8% during the second quarter. Acadian Asset Management LLC now owns 38,010 shares of the company’s stock worth $954,000 after buying an additional 29,762 shares during the last quarter. Headlands Technologies LLC boosted its position in shares of Genmab A/S by 1,702.8% in the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after acquiring an additional 4,853 shares during the period. Finally, Oppenheimer Asset Management Inc. grew its stake in shares of Genmab A/S by 26.3% in the second quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock worth $5,480,000 after acquiring an additional 45,376 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Price Performance

GMAB stock opened at $21.72 on Tuesday. The firm has a market capitalization of $14.37 billion, a P/E ratio of 21.09, a P/E/G ratio of 0.63 and a beta of 0.97. Genmab A/S has a 52-week low of $19.85 and a 52-week high of $31.88. The company’s 50 day simple moving average is $21.29 and its 200-day simple moving average is $24.17.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). The firm had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period last year, the firm earned $0.47 earnings per share. Sell-side analysts predict that Genmab A/S will post 1.28 EPS for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.